convEyXO

Executive Summary

ConvEyXO is a Belgian biotechnology company founded in 2018 and based in Leuven, dedicated to developing RNA-enhanced exosome therapeutics for degenerative diseases. The company's platform leverages engineered exosomes as natural delivery vehicles, loaded with miRNA payloads to restore cellular balance and target inflammation and aging at their roots. This innovative approach aims to extend healthspan by addressing the biological drivers of degeneration. While still in the pre-clinical stage, ConvEyXO's technology holds promise for tackling diseases with high unmet medical need. The company has not disclosed total funding or valuation, but its focus on exosome-based drug delivery positions it in a rapidly growing field with major pharma interest. To advance toward clinical development, ConvEyXO will need to secure substantial financing, generate robust preclinical proof-of-concept data, and potentially form strategic partnerships. The road ahead includes completing IND-enabling studies and navigating regulatory pathways. Given the early stage and lack of disclosed pipeline, conviction is tempered by the typical risks of pre-clinical biotech, including funding uncertainty and scientific validation. However, the unique approach and growing interest in exosome therapeutics provide a solid foundation for future milestones.

Upcoming Catalysts (preview)

• Q4 2025Completion of key preclinical efficacy studies70% success
• Q2 2026Series A financing round60% success
• Q3 2026Strategic partnership with a pharmaceutical company40% success